Medication info
Lozatam Plus Tablets

Lozatam Plus Tablets

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Ildong Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablets
Packaging
30 tablets, 300 tablets/bottle
Approval status
Active

MFDS item code 200809791 · Notified 2008.09.24 · Insurance code 642903050

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, initiate treatment with this medicine when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: Concomitant therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Initiate treatment with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Initiate treatment with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be initiated with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. Use of this medicine is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide-type medicines in these patients. ○ Patients with hepatic impairment Use of this medicine is not recommended in patients with hepatic impairment requiring dose adjustment, because the initial losartan potassium dose of 25 mg for these patients cannot be administered with this medicine.
Child dose
Pediatric patients (under 18 years of age): There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Ildong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used additionally in patients with hypertension when blood pressure control is insufficient with monotherapy to effectively lower and control blood pressure.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, initiate treatment with this medicine when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: Concomitant therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Initiate treatment with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Initiate treatment with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be initiated with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. Use of this medicine is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide-type medicines in these patients. ○ Patients with hepatic impairment Use of this medicine is not recommended in patients with hepatic impairment requiring dose adjustment, because the initial losartan potassium dose of 25 mg for these patients cannot be administered with this medicine.

Child dose

Pediatric patients (under 18 years of age): There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, particularly in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. Patients who have had allergic reactions to any ingredients in this medication or to the medication itself, patients with severely impaired kidney or liver function, patients with certain electrolyte imbalances should not take this medication. In some patients, such as those with hypotension, kidney dysfunction, liver disease, gout, and the elderly, this medication should be used with caution, particularly if blood pressure is too low or if there are issues with renal blood vessels. This medication may affect serum potassium levels, so if taken with potassium supplements or other medications containing potassium, the risk of hyperkalemia should be discussed with a physician. Regular monitoring of blood pressure, kidney function, and electrolyte levels is necessary while taking this medication, and healthcare providers should be consulted immediately if any abnormal symptoms arise. Side effects such as dizziness, drowsiness, cough, and skin rash may occur, so caution is necessary when driving or operating machinery. Due to the hydrochlorothiazide component, electrolyte imbalances may occur, and changes in blood sugar and uric acid levels may occur, so caution is particularly necessary for patients with diabetes or gout. This medication may react sensitively to sunlight, so prolonged exposure to ultraviolet light should be avoided, and if any skin abnormalities occur, a physician should be consulted immediately. Women who are pregnant or planning to become pregnant, as well as nursing mothers, must consult with healthcare providers before taking this medication; and breastfeeding or medication may need to be discontinued if necessary. Safety has not been established for use in children or adolescents, so it should not be used in this population. In case of overdose, symptoms such as hypotension and tachycardia may occur, so strict adherence to the dosage is required, and immediate medical attention should be sought if abnormal symptoms occur. This medication should not be taken with grapefruit juice, and the possibility of interactions with other medications should be considered; therefore, patients must inform healthcare providers if they are taking any other medications. This medication should be stored out of reach of children and kept sealed in its original container to prevent misuse or degradation of quality.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • back pain
  • dizziness
Show 133 more
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
  • exfoliative dermatitis
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle stiffness
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neurogenic hypersensitivity
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disturbances
  • drowsiness
  • tremor
  • dizziness
  • shortness of breath
  • epistaxis
  • nasal congestion
  • throat discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus obstruction
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reactions
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • taste disturbances
  • tinnitus
  • erectile dysfunction
  • nocturia
  • frequent urination
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • salivary gland inflammation
  • spasms
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • hemolytic anemia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • fever
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • hyperuricemia
  • muscle cramps
  • restlessness
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • skin and mucous membrane syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal exudate
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythematous skin syndrome
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a tightly sealed container that blocks light. Additionally, it is important to store it at room temperature, which is between 1 degree and 30 degrees Celsius, to maintain its effectiveness.

Appearance and packaging

Appearance

Yellow oval film-coated tablets

Package unit

30 tablets, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.